206 related articles for article (PubMed ID: 11102561)
41. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events.
Freston JW
Am J Med; 1999 Dec; 107(6A):78S-88S; discussion 89S. PubMed ID: 10628597
[TBL] [Abstract][Full Text] [Related]
42. Nonsteroidal anti-inflammatory drugs (NSAIDs) and the kidney.
Pugliese F; Cinotti GA
Nephrol Dial Transplant; 1997 Mar; 12(3):386-8. PubMed ID: 9075111
[TBL] [Abstract][Full Text] [Related]
43. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition.
Brater DC
Am J Med; 1999 Dec; 107(6A):65S-70S; discussion 70S-71S. PubMed ID: 10628595
[TBL] [Abstract][Full Text] [Related]
44. Coxibs--beyond the GI tract: renal and cardiovascular issues.
DeMaria AN; Weir MR
J Pain Symptom Manage; 2003 Feb; 25(2 Suppl):S41-9. PubMed ID: 12604156
[TBL] [Abstract][Full Text] [Related]
45. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.
Bosch-Marcè M; Clària J; Titos E; Masferrer JL; Altuna R; Poo JL; Jiménez W; Arroyo V; Rivera F; Rodés J
Gastroenterology; 1999 May; 116(5):1167-75. PubMed ID: 10220509
[TBL] [Abstract][Full Text] [Related]
46. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
Bjarnason I; Thjodleifsson B
Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
[TBL] [Abstract][Full Text] [Related]
47. Cyclo-oxygenase isoenzymes: physiological and pharmacological role.
Kam PC; See AU
Anaesthesia; 2000 May; 55(5):442-9. PubMed ID: 10792135
[TBL] [Abstract][Full Text] [Related]
48. Pharmacology and clinical action of COX-2 selective NSAIDs.
Bovill JG
Adv Exp Med Biol; 2003; 523():201-14. PubMed ID: 15088852
[No Abstract] [Full Text] [Related]
49. From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal.
Kremer J
J Rheumatol Suppl; 2000 Oct; 60():9-12. PubMed ID: 11032096
[TBL] [Abstract][Full Text] [Related]
50. Renal effects of cyclooxygenase-2 selective inhibitors.
Harris CJ; Brater DC
Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):603-10. PubMed ID: 11496053
[TBL] [Abstract][Full Text] [Related]
51. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity.
Khan KN; Venturini CM; Bunch RT; Brassard JA; Koki AT; Morris DL; Trump BF; Maziasz TJ; Alden CL
Toxicol Pathol; 1998; 26(5):612-20. PubMed ID: 9789947
[TBL] [Abstract][Full Text] [Related]
52. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
Wallace JL
Am J Med; 1999 Dec; 107(6A):11S-16S; discussion 16S-17S. PubMed ID: 10628589
[TBL] [Abstract][Full Text] [Related]
53. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
Savage R
Drugs Aging; 2005; 22(3):185-200. PubMed ID: 15813652
[TBL] [Abstract][Full Text] [Related]
54. [Recent development of selective cyclooxygenase-2 inhibitors].
Kawai S
Nihon Rinsho; 2002 Dec; 60(12):2370-7. PubMed ID: 12510364
[TBL] [Abstract][Full Text] [Related]
55. [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase].
Stichtenoth DO; Zeidler H; Frölich JC
Med Klin (Munich); 1998 Jul; 93(7):407-15. PubMed ID: 9711054
[TBL] [Abstract][Full Text] [Related]
56. [Mechanism of inhibition OF COX-2 and COX-3 in gastrointestinal damage induced by NSAID in rats ].
Laudanno OM; San Miguel P; Aramberry LJ; Cesolari JA
Acta Gastroenterol Latinoam; 2003; 33(4):183-5. PubMed ID: 14708469
[TBL] [Abstract][Full Text] [Related]
57. Future trends in the development of safer nonsteroidal anti-inflammatory drugs.
Wolfe MM
Am J Med; 1998 Nov; 105(5A):44S-52S. PubMed ID: 9855176
[TBL] [Abstract][Full Text] [Related]
58. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.
Bennett K; Teeling M; Feely J
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):645-9. PubMed ID: 12942226
[TBL] [Abstract][Full Text] [Related]
59. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.
McGeer PL
Drugs Aging; 2000 Jul; 17(1):1-11. PubMed ID: 10933512
[TBL] [Abstract][Full Text] [Related]
60. COX-2 in brain and spinal cord implications for therapeutic use.
Hoffmann C
Curr Med Chem; 2000 Nov; 7(11):1113-20. PubMed ID: 11032961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
